Literature DB >> 7855181

Determination of plasma and brain concentrations of SCH 39166 and their correlation to conditioned avoidance behavior in rats.

C E Tedford1, V L Coffin, V Ruperto, M Cohen, R D McQuade, R Johnson, H K Kim, C C Lin.   

Abstract

Plasma and brain concentrations of the dopamine D1 receptor antagonist, SCH 39166, were measured and compared to behavioral activity in the conditioned avoidance response paradigm (CAR). SCH 39166 was administered at two behaviorally active doses (1 mg/kg, SC and 10 mg/kg, PO) and the time course for CAR activity was compared with the plasma and brain concentrations of unconjugated SCH 39166. Conjugation and N-demethylation of SCH 39166 after oral administration were also determined and first pass metabolism examined. Results from these studies demonstrated a similar time-dependent disappearance of unconjugated SCH 39166 from both the plasma and brain, independent of route of administration. Brain concentrations of SCH 39166 were approximately 5-fold higher than corresponding plasma concentrations, regardless of route. However, plasma and brain concentrations of unconjugated SCH 39166 were higher after SC administration of 1.0 mg/kg, than after PO administration of 10 mg/kg, suggesting a substantial first pass metabolism of SCH 39166. In addition, total (conjugated and unconjugated) plasma concentrations of SCH 39166 were at least 10-fold higher than unconjugated concentrations of SCH 39166 after PO administration of 10 mg/kg, demonstrating that a high proportion of drug was conjugated. Metabolism to the N-desmethyl analog, SCH 40853, was observed after PO administration of 10 mg/kg SCH 39166 and a high proportion of conjugation of the desmethyl analog was also seen. Finally, plasma concentrations of unconjugated SCH 39166 exhibited a high positive correlation (r = 0.934, P < 0.001) with brain concentrations of unconjugated SCH 39166.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7855181     DOI: 10.1007/bf02245697

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats.

Authors:  A B Davidson; E Weidley
Journal:  Life Sci       Date:  1976-06-01       Impact factor: 5.037

2.  In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.

Authors:  R D McQuade; R A Duffy; V L Coffin; A Barnett
Journal:  Eur J Pharmacol       Date:  1992-04-29       Impact factor: 4.432

3.  SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in cebus monkeys.

Authors:  V L Coffin; D McHuch; R E Chipkin; A Barnett
Journal:  Neurochem Int       Date:  1992-03       Impact factor: 3.921

4.  Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

Authors:  R E Chipkin; L C Iorio; V L Coffin; R D McQuade; J G Berger; A Barnett
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

5.  Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.

Authors:  V L Coffin; M B Latranyi; R E Chipkin
Journal:  J Pharmacol Exp Ther       Date:  1989-06       Impact factor: 4.030

6.  Characterization of a rat liver glucuronosyltransferase that glucuronidates the selective D1 antagonist, SCH 23390, and other benzazepines.

Authors:  C E Tedford; V B Ruperto; A Barnett
Journal:  Drug Metab Dispos       Date:  1991 Nov-Dec       Impact factor: 3.922

7.  Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices.

Authors:  C E Tedford; G Crosby; L C Iorio; R E Chipkin
Journal:  Eur J Pharmacol       Date:  1992-02-11       Impact factor: 4.432

8.  Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood.

Authors:  J Hietala; T Seppäla; J Lappalainen; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

10.  In vivo binding of SCH 39166: a D-1 selective antagonist.

Authors:  R D McQuade; R A Duffy; V L Coffin; R E Chipkin; A Barnett
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

  10 in total
  1 in total

1.  Effects of the dopamine D1 receptor antagonist SCH 39166 on the ingestive behaviour of alcohol-preferring rats.

Authors:  I Panocka; R Ciccocioppo; M Mosca; C Polidori; M Massi
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.